NCT02260440View on ClinicalTrials.gov

A Phase 2 Study of Pembrolizumab (MK-3475) in Combination With Azacitidine in Subjects With Chemo-refractory Metastatic Colorectal Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

January 31, 2015

Primary Completion Date

March 31, 2016

Study Completion Date

September 30, 2017

Conditions
Metastatic Colorectal Cancer
Interventions
DRUG

Pembrolizumab

Pembrolizumab will be given at 200 mg every 21 days

DRUG

Azacitidine

Azacitidine will be given at 100 mg daily subcutaneous injection on days 1-5 every 21 days.

Trial Locations (1)

15232

Hillman Cancer Center, Pittsburgh

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Anuradha Krishnamurthy

OTHER

NCT02260440 - A Phase 2 Study of Pembrolizumab (MK-3475) in Combination With Azacitidine in Subjects With Chemo-refractory Metastatic Colorectal Cancer | Biotech Hunter | Biotech Hunter